Royalty Pharma And Ferring Pharmaceuticals Ink $500M Royalty Deal For Innovative Intravesical Gene Therapy Adstiladrin
Portfolio Pulse from Benzinga Newsdesk
Royalty Pharma and Ferring Pharmaceuticals have signed a $500 million royalty deal for the innovative intravesical gene therapy Adstiladrin. The deal will provide Royalty Pharma with a significant share of future global net sales of Adstiladrin.
August 24, 2023 | 6:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The $500 million royalty deal with Ferring Pharmaceuticals for Adstiladrin could provide a significant boost to Royalty Pharma's future revenues.
The deal provides Royalty Pharma with a significant share of future global net sales of Adstiladrin. This could lead to increased revenues for the company, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100